Screening Canadians at high risk for early heart failure diagnosis
Tests a blood marker and heart scans to find heart failure earlier in adults.
Plain-language title generated from the registry record
Registry title: Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure
Key facts
- Where
- Montreal, Sherbrooke, and Vancouver, CanadaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 40 who are at risk of heart failure but have not been diagnosed with it. It tests earlier detection of heart failure.
- Age
- Over 40 years old
- Sex
- Men and women
- Disease stage
- No heart failure diagnosis yet. People need at least two risk factors for heart failure, such as coronary artery disease, diabetes, persistent or permanent atrial fibrillation, previous stroke, peripheral artery disease, chronic kidney disease, regular loop diuretic use for more than 30 days, or COPD.
- Earlier treatment
- People cannot have had renal replacement therapy.
Main reasons for not taking part
- Cannot give informed consent, for example due to significant cognitive impairment
- Previous diagnosis of heart failure of any kind
- Renal replacement therapy
- Any other reason the investigator thinks the person should not take part, for example a diagnosis that may affect survival during the study
Read by machine on 9 November 2026.
Where in Canada
- Montreal Heart InstituteMontreal, CanadaNot yet recruiting
- University of SherbrookeSherbrooke, CanadaNot yet recruiting
- Vancouver General HospitalVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cardiology Research UBC
- Trial code
- NCT05859048
- Record updated
- 5 November 2026
- Original description
The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.Read full original descriptionShow less
Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians
The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.
The main question[s] it aims to answer are:
• will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care?
Participants will be enrolled and randomized to either standard of care (SOC) or intervention arm:
SOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure.
Intervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (>125pg/ml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months
Inclusion: Male or female > 40 years of age; Informed consent; At least two additional risk factors for Heart Failure (HF):; Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or >70% left anterior descending, circumflex or right coronary artery)); Diabetes type 1 or 2; Persistent or permanent atrial fibrillation; Previous ischemic or embolic stroke; Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis >50% of major peripheral arterial vessel; Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)<60 milliliters per minute (mL/min)/1.73m2 or eGFR 60-90 mL/min/1.73m2 and urine albumin-creatinine ration (UACR) >300mg/g); Regular loop diuretic use for >30 days within 12 months prior to consent; Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or treatment with national guidance advocated COPD therapy.
Exclusion: Renal replacement therapy; Inability to give informed consent (e.g. due to significant cognitive impairment); Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause; Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.